SciSparc Ltd., a clinical-stage pharmaceutical company that specializes in central nervous system disorders and rare diseases, has recently been granted a patent by the Canadian Intellectual Property Office for its core technology. This technology combines cannabinoids with n-acylethanolamines to improve the safety and effectiveness of cannabinoids at lower doses. This new patent is a valuable addition to SciSparc’s intellectual property portfolio and supports the development of the company’s proprietary technologies.
As CEO of SciSparc, Oz Adler highlighted the importance of this patent in strengthening the company’s global intellectual property rights. He also emphasized SciSparc’s dedication to creating technologies for treating central nervous system disorders, which he believes will benefit the company’s investors.
SciSparc is currently working on drug development programs for various conditions such as Tourette Syndrome, Alzheimer’s disease, pain, ASD, and status epilepticus, using both THC and non-psychoactive CBD. Additionally, the company has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.com.
The information in this article was generated with support from AI technology and reviewed by an editor before publication.
